Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In this interview, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the process of organizing the midostaurin clinical trials by collaborating with experts throughout North America, Europe and Australia (NCT00651261). Although midostaurin is already FDA-approved, analysis of the collected data from the trials is still being carried out to find out the causes of a low response to the drug, which may lead to a further understanding of AML in the future. Recorded from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Midostaurin: the first drug to receive approval for AML since 2000
